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Herbal medicinal products (HMPs) that interact with the mediators of infl ammation are used in the treatment 
of rheumatoid arthritis (RA). The aim of this study was to update a previous systematic review published in 
2000. We searched electronic databases (MEDLINE, EMBASE, CISCOM, AMED, CINAHL, Cochrane reg-
isters) to June 2007, unrestricted by date or language, and included randomized controlled trials that compared 
HMPs with inert (placebo) or active controls in patients with rheumatoid arthritis. Five reviewers contributed 
to data extraction. Disagreements were discussed and resolved by consensus with reference to Cochrane guide-
lines and advice from the Cochrane Collaboration.
Twenty studies (10 identifi ed for this review update, and 10 of the 11 studies of the original review) investi-
gating 14 HMPs were included. Meta-analysis was restricted to data from previous seven studies with oils from 
borage, blackcurrant and evening primrose containing gamma linolenic acid (GLA). GLA doses equal or higher 
than 1400 mg/day showed benefi t in the alleviation of rheumatic complaints whereas lower doses (∼500 mg) 
were ineffective. Three studies compared products from Tripterygium wilfordii (thunder god vine) to placebos 
and returned favorable results but data could not be pooled because the interventions and measures differed. 
Serious adverse effects occurred in one study. In a follow-up study all side effects were mild to moderate and 
resolved after the intervention ceased, but time to resolution was variable. Two studies comparing Phytodolor 
NR to placebo were of limited use because some measures were poorly defi ned. The remaining studies, each 
considering differing HMPs, were assessed individually.
For most HMPs used in the treatment of RA, the evidence of effectiveness was insuffi cient to either recom-
mend or discourage their use. Interventions with HMPs containing GLA or Tripterygium wilfordii extract 
appear to produce therapeutic effects but further investigations are warranted to prove their effectiveness and 
safety. Copyright © 2009 John Wiley & Sons, Ltd.
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INTRODUCTION
The American College of Rheumatology (ACR) has 
published recommendations for the medical manage-
ment of rheumatoid arthritis (RA; ACR, 2002). Ulti-
mate management goals are ‘to prevent or control of 
joint damage, prevent loss of function, and decrease 
pain’. Nonsteroidal anti-infl ammatory drugs (NSAIDs), 
glucocorticoid joint injection, and low-dose prednisone 
are recommended for symptom control. Also advised 
is that the majority of patients with newly diagnosed 
RA commence disease-modifying antirheumatic drug 
(DMARD) therapy within three months of diagnosis, 
together with patient education (e.g., Arthritis Self-
Management Program; Lorig and Holman, 1989), 
and physical and occupational therapies. Herbal medic-
inal products (HMPs) are not among the options 
recommended.
Later in the guidelines, the authors argue that ‘given 
the chronic waxing and waning course of RA, a longi-
tudinal treatment plan needs to be developed, and the 
patient should be involved in developing the plan. The 
discussion should address disease prognosis and treat-
ment options, taking into account the costs, adverse 
effects, expected time for response, the patient’s risk 
factors and co-morbid conditions, monitoring require-
ments of pharmacologic agents, and the patient’s pref-
erences. Expectations for treatment and potential 
barriers to carrying out the recommendations should be 
discussed.’ (ACR, 2002). This charge to include the 
patient in care planning and to consider the patient’s 
concerns and preferences may be viewed as a case for 
considering the use of herbal therapies in the treatment 
* Correspondence to: Melainie Cameron, School of Exercise Science, 
Australian Catholic University, PO Box 456, Virginia, QLD, 4014, 
Australia.
E-mail: melainie.cameron@acu.edu.au
Received 19 July 2009
Copyright © 2009 John Wiley & Sons, Ltd. Accepted 09 August 2009
PHYTOTHERAPY RESEARCH
Phytother. Res. 23: 1647–1662 (2009)
Published online in Wiley InterScience
(www.interscience.wiley.com) DOI: 10.1002/ptr.3006
Copyright © 2009 John Wiley & Sons, Ltd. Phytother. Res. 23: 1647–1662 (2009)
DOI: 10.1002/ptr
1648 M. CAMERON ET AL.
schedule of RA since many patients of rheumatologists 
use complementary or alternative medicines (CAM), 
and under-report use of these therapies to medical prac-
titioners (Cronan et al., 1989; Boisset and Fitzcharles, 
1994; Buchbinder et al., 2002). Patients’ reasons for 
using CAM include: (1) dissatisfaction with conven-
tional treatment; (2) a need to control their own health 
care; (3) agreement with the philosophy and ideas of 
alternative therapies (Astin, 1998); and (4) desire to 
avoid side effects of conventional therapies (Ernst et al., 
1995). Whereas in Chinese medicine ‘Lei Gong Teng’ 
(thunder god vine or ‘three-wing nut’) has been used 
for centuries to treat infl ammatory tissue swelling 
(MacPherson and Blackwell, 1994), most popular anti-
rheumatic remedies in European include preparations 
from the bark of Salix species, the root of devil’s claw 
(Harpagophytum procumbens) and the aerial parts of 
nettle (Urtica dioica) (Chrubasik and Wink, 1998; 
Chrubasik and Eisenberg, 1998).
RA is a systemic infl ammatory disorder that affects 
approximately 1% of the population worldwide, more 
females than males. Its predominant symptoms include 
pain, stiffness, and swelling of peripheral joints. RA 
may be mild and self-limiting, but in other cases may 
rapidly progress into a multisystem infl ammation with 
irreversible joint destruction and increased risk of mor-
tality. Negative prognostic factors for severity include 
presence of rheumatoid factor or HLADR4 alleles, 
early development of joint erosions, increasing number 
of affected joints, early disability, older age at onset, 
fewer years of formal education, and presence of extra-
articular features. Synovial infl ammation, cartilage 
destruction, and bone erosions characterise the patho-
physiological joint processes of RA in which several 
proinfl ammatory pathways are involved (Lee and 
Weinblatt, 2001). Tumor necrosis factor alpha (TNFα), 
interleukin 1 (IL-1), interleukin 6 (IL-6), and receptor 
activator of nuclear factor kappa-B ligand (RANKL) 
play central roles in synovitis and joint destruction. For 
example, increased expression of IL-1 and TNFα results 
in inhibition of bone formation via the stimulation of 
nitric oxide production in osteoblasts; increased IL-6 
expression accelerates bone resorption. RANKL acti-
vates osteoclasts via receptor factor kappa-B (RANK), 
the receptor for RANKL on the osteoclast surface. 
Activated metalloproteinases and neutral proteases 
degrade structural proteins of the extracellular matrix. 
Activated T cells, chemokines, adhesion molecules 
angiogenetic cytokines, growth factors and colony- 
stimulating factors, as well as cyclooxygenase (COX) 
and lipoxygenase (LOX) also participate in the infl am-
matory process (O’Gradaigh et al., 2004).
From in vitro research it seems likely, that HMPs 
interact with infl ammation and cytokine-induced 
damage. Although the exact mechanisms of action have 
not yet been elucidated, there is no doubt that all plant 
materials act via several pathways (some not yet identi-
fi ed), including inhibition of COX and/or LOX, inhibi-
tion of cytokine release, inhibition of elastase or 
hyaluronidase besides exerting antioxidative activity 
(Chrubasik et al., 2007; for further details see Tables 1a 
and 1b). Capsaicin has a different mode of action; it 
alters synthesis, storage, transport, and release of sub-
stance P (Buck and Burks, 1986) and thus, the transmis-
sion of pain, stimulates vanilloid receptors (Dedov and 
Roufogalis, 2000), and also destroys reversibly the fi ne 
nerve endings (Nolano et al., 1999) as well as inhibiting 
LOX (Flynn et al., 1986).
The aim of this review was to update an existing sys-
tematic review on the effectiveness of HPMs in the 
treatment of rheumatoid arthritis (Little and Parsons, 
2000) by adding data from relevant randomized con-
trolled trials published in the period from January 2000 
to June 2007.
METHODS
All randomized controlled (placebo or active control) 
parallel and crossover trials examining the effects of 
herbal interventions for treating rheumatoid arthritis 
were included if patients were diagnosed with rheuma-
toid arthritis according to American College of Rheu-
matology (ACR) criteria (Arnett et al., 1988). Studies 
with samples defi ned according to vague descriptions 
(e.g., ‘joint pain’) were not considered.
Any form of herbal intervention compared with an 
inert (placebo) or active control, via any route of 
administration, was included. Herbal therapy used in 
conjunction with other treatments or combined with a 
non-herbal substance were also included if the effect 
of the non-herbal intervention was: (1) consistent 
among all groups; and (2) quantifi able. Herbal inter-
vention included any plant preparation (crude plant 
material, powder, extract, mixture) but excluded home-
opathy, aromatherapy, or any preparation of synthetic 
origin.
Primary outcomes included: changes in assessed 
clinical measures of effectiveness (e.g., mobility, grip 
strength), changes in self-reported measures of effec-
tiveness (e.g., pain, use of medication), any adverse 
reaction (AE). Secondary outcomes included: quality of 
life indicators, satisfaction.
We searched the following electronic databases 
(from 1966): Cochrane Musculoskeletal Group 
Register; Cochrane Complementary Medicine Field 
Register; Cochrane Controlled Trials Register (CCTR); 
MEDLINE; EMBASE; CISCOM; AMED; CINAHL; 
Dissertation Abstracts; BIDS ISI. Thesaurus and free text 
searches were performed across each database to combine 
the terms arthritis and herbal medicine. The general struc-
ture of the search strategy was arthritis (or synonyms) and 
herb (or synonyms). No methodological fi lter was applied 
and the search was not limited by language.
The following keywords were applied: arthritis, rheu-
matoid arthritis, reactive arthritis, adjuvant arthritis, 
infective arthritis, osteoarthritis, gouty arthritis, juve-
nile rheumatoid arthritis, psoriatic arthritis, periarthri-
tis. Free text search terms included arthrit* and also 
combined the terms hip, knee, joint, musculoskeletal 
and pain, infl ammation, movement, stiffness, medicine 
herbal, medicines herbal, herbal medicine, drugs 
Chinese herbal, plants medicinal. Free text search terms 
included herb* or plant*. On completion of the primary 
search, a secondary search combined the terms arthritis 
(or synonym) and each named herb.
All titles and abstracts identifi ed from electronic 
databases and other searches were independently exam-
ined by two investigators (CL, MC). A full manuscript 
was retrieved for each record that had the possibility of 
meeting the review criteria. Three reviewers (CL, MC, 
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Table 1b. Cytokine inhibition suggested from in vitro studies (GLA gamma-linolenic acid)
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Inhibition of Cytokines
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SC) independently assessed eligibility of retrieved 
studies for review according to the inclusion criteria. 
Five reviewers (MC, SC, AB, JG, TP) contributed to 
data extraction. Data were extracted from each eligible 
study by two reviewers acting independently. Where a 
study was defi ned as a crossover trial, data were 
extracted only up to the point of crossover in order that 
these data could be compared with those derived from 
parallel trials.
Two review authors (MC, SC) independently assessed 
the risk of bias of each included trial, against key crite-
ria: random sequence generation; allocation conceal-
ment; blinding of participants, personnel and outcomes; 
incomplete outcome data; selective outcome reporting; 
and other sources of bias, in accordance with methods 
recommended by the Cochrane Collaboration (Higgins 
and Green, 2008). Each of these criteria was explicitly 
judged using: A = yes (low risk of bias); B = no (high 
risk of bias); C = unclear (either lack of information or 
uncertainty over the potential for bias). Potential dis-
agreements were discussed and resolved by referring to 
the original protocol and, if necessary, arbitration by 
member(s) of the Cochrane Steering Group.
Descriptive results are reported for all included 
studies. Studies with the same outcome measures 
and comparators were included in the meta-analyses. 
For dichotomous outcomes, odds ratios or relative 
risks were calculated. For continuous outcomes, a 
mean difference (MD) was calculated and confi dence 
intervals reported at 95%. Chi-square and I2 tests of 
heterogeneity were conducted and fi xed or random 
effects models were chosen appropriately. Threshold 
values (p and I2) for heterogeneity were not determined 
a priori; rather heterogeneity was reported using 
both chi-squared and I2 values, with I2 of 30–60% con-
sidered to represent moderate heterogeneity, and I2 of 
more than 60% as substantial heterogeneity. This cat-
egorical classifi cation was consistent with the chi-square 
analyses if p = 0.10 was accepted as the arbiter of 
signifi cance. Reasons for heterogeneity were explored 
by reviewing study designs and results. I2 values of 80% 
or greater were considered to represent unacceptable 
heterogeneity indicating that the studies could not 
be rationally pooled.
Main results of the review are presented in summary 
of fi ndings tables, including an overall grading of the 
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evidence using the GRADE approach (Schunemann 
et al., 2008a), and a summary of the available data 
on the main outcomes, as described in the Cochrane 
Handbook for Systematic Reviews of Interventions 
(Schunemann et al., 2008b). Quality of evidence for 
each herbal intervention is classifi ed as High, Moderate, 
Low, or Very Low, as an indication of confi dence in 
the results of studies and meta-analyses. For example, 
high-quality evidence is robust and further studies 
are very unlikely to change our confi dence in the 
estimate of effect; conversely, low-quality evidence 
is open to question and further research is very 
likely to have an important impact on our confi dence 
in the estimate of effect and may change the 
estimate.
RESULTS
From approximately 2500 citations, a total of ten 
new studies, including four studies published prior 
to 2000, were identifi ed for inclusion in the updated 
review (Meier, 1987; Eberl et al., 1988; McCarthy and 
McCarthy 1992; Sander et al., 1998; Chopra et al., 2000; 
Mur et al., 2002; Tao et al., 2002; Cibere et al., 2003; 
Biegert et al., 2004; Song et al., 2007). These studies 
were added to 10 of the 11 studies included in the origi-
nal review (Belch et al., 1988; Jäntti et al., 1989a; Pattrick 
et al., 1989; Tao et al., 1989; Brzeski et al., 1991; Deal et 
al., 1991; Leventhal et al., 1993; 1994; Watson et al., 
1993; Zurier et al., 1996). One study included in the 
original review was excluded because participants with 
any form of arthritic disease were recruited (Mills et al., 
1996). Other reasons for excluding studies were: (1) not 
a randomized controlled trial; (2) discussion paper; (3) 
full study details not available; (4) unable to identify the 
herbal components of the intervention; (5) case series; 
(6) review paper; (7) inappropriate statistical analysis; 
or (8) duplicate publication.
Seventeen of the studies were of parallel design 
(Meier, 1987; Belch et al., 1988; Eberl et al., 1988; Jäntti 
et al., 1989a; Pattrick et al., 1989; Brzeski et al., 1991; 
Deal et al., 1991; McCarthy and McCarthy, 1992; 
Leventhal et al., 1993; 1994; Watson et al., 1993; Sander 
et al., 1998; Chopra et al., 2000; Mur et al., 2002; Tao 
et al., 2002; Cibere et al., 2003; Biegert et al., 2004; 
Song et al., 2007), one used a crossover design (Tao 
et al., 1989) and one a partial crossover design (Zurier 
et al., 1996).
The 20 studies evaluated the effectiveness of 14 HMPs 
as listed in Table 2. Three of these were not fully char-
acterized so that the study could not be repeated (Sander 
et al., 1998; Chopra et al., 2000; Cibere et al., 2003). 
Herbal mono-preparations for oral use included seed 
oils of borage, blackcurrant and evening primrose as 
plant sources of gamma linolenic acid (GLA) and prepa-
rations from the herb of Tanacetum parthenium (fever-
few), the root of Uncaria tomentosa (cat’s claw), the 
bark of a Salix species (willow bark), the gum resin of 
Boswellia serrata, and the root of Tripterygium wilfordii 
(thunder god vine). The latter was also administered 
in form of a topical product as was capsaicin in form 
of creams. Herbal mixtures for oral use included the 
Ayurvedic formula RA-1, SKI306X, and Phytodolor 
NR.
One study (Belch et al., 1988) included three parallel 
arms comparing evening primrose oil, a mixture of 
evening primrose oil and fi sh oil, and placebo, but only 
the evening primrose oil and placebo arms were consid-
ered in this review. One study included data on patients 
with OA as well as RA but data were presented sepa-
rately (Deal et al., 1991). Overall, the studies reported 
a wide variety of clinical outcomes and some studies 
also reported biochemical outcomes (Belch et al., 1988; 
Jäntti et al., 1989b; Pattrick et al., 1989; Tao et al., 1989; 
Leventhal et al., 1993; 1994; Watson et al., 1993; Sander 
et al., 1998). Only clinical outcomes were considered in 
this review.
Methodological quality of each study was assessed 
independently by two reviewers according to the 
criteria described in the methods (Higgins and Green, 
2008; Schunemann et al., 2008a; 2008b). Quality of the 
included studies was variable, and should be taken into 
account when interpreting results. In general, method-
ological quality of the new studies was superior to that 
of the older studies, suggesting that quality of research 
design and reporting has improved since 2000 (Chopra 
et al., 2000; Biegert et al., 2004; Song et al., 2007).
Only three studies adequately met all six validity cri-
teria and thus were at minimal risk of bias (Chopra 
et al., 2000; Biegert et al., 2004; Song et al., 2007). In six 
studies (Belch et al., 1988; Jäntti et al., 1989a; Pattrick 
et al., 1989; Sander et al., 1998; Mur et al., 2002; Tao 
et al., 2002) the method of randomization and in one 
study (Meier, 1987) the method of double-blinding were 
not described, and in one study withdrawals were not 
reported (Cibere et al., 2003). In eight studies neither 
the method of randomization nor the method of double-
blinding were described (Eberl et al., 1988; Tao et al., 
1989; Brzeski et al., 1991; Deal et al., 1991; Leventhal 
et al., 1993; 1994; Watson et al., 1993; Zurier et al., 1996).
Oils containing gammalinolenic acid (GLA)
Seven studies investigated the effects of plant sourced 
GLA on a total of 286 participants. Three of them 
investigated evening primrose seed oils (EPO; Belch 
et al., 1988; Jäntti et al., 1989a; Brzeski et al., 1991;), 
two blackcurrant seed oils (Watson et al., 1993; Leven-
thal et al., 1994) and two borage seed oils (Leventhal 
et al., 1993; Zurier et al., 1996). The approximate daily 
intake of GLA varied from 525 mg (Watson et al., 1993) 
to 2800 mg (Zurier et al., 1996). Although the active 
principle of the seed oils may be slightly different 
due to the oil composition, studies were considered 
together based on the daily quantity of gammalinolenic 
acid, the patients had consumed. Placebo oils included 
olive oil (Jäntti et al., 1989a; Brzeski et al., 1991), 
sunfl ower oil (Watson et al., 1993; Zurier et al., 1996), 
liquid paraffi n (Belch et al., 1988), cottonseed oil 
(Leventhal et al., 1993), and soybean oil (Leventhal 
et al., 1994).
Small daily GLA doses
Three studies investigating GLA doses between 525 mg 
and 540 mg were incompletely reported and data could 
not be extracted (Belch et al., 1988; Brzeski et al., 1991; 
Watson et al., 1993). No signifi cant improvements in the 
Copyright © 2009 John Wiley & Sons, Ltd. Phytother. Res. 23: 1647–1662 (2009)
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provided high-quality evidence that six months of treat-
ment with oil containing at least 1400 mg GLA improves 
self-reported pain assessed on a VAS in RA patients.
In the other study (Jäntti et al., 1989a), 100 mm VAS 
pain scores were reported as absolute values after 12 
weeks of intervention. These results favored the 
placebo group with a non-signifi cant mean difference of 
6.00 (CI −16.36 to 28.36, p = 0.60). It is unclear why these 
results differ from those of the other three large dose 
studies, but possible explanations include a shorter 
intervention period (12 weeks), use of a non-inert oil 
(olive oil) in the placebo group, and a small sample size 
that may have contributed to Type II error.
Pain assessed on a categorical scale (0–4,none to very 
severe) and reported as percentage change from base-
line in the three longer-term studies showed near sig-
nifi cant improvement in the GLA compared with the 
placebo group (MD −34.19, CI −71.57 to 3.18, p = 0.07). 
These studies are moderately heterogeneous (chi-
square 4.95, I2 = 59.6%, p = 0.08), but within acceptable 
thresholds for data pooling.
Duration of morning stiffness (MS) was measured in 
minutes. Absolute MS values after 12 weeks showed no 
improvement in the GLA versus the placebo group 
(MD −5.00, CI −41.68 to 31.68, p = 0.79; Jäntti et al., 
1989a). Measures of MS, adjusted to change scores from 
baseline, were pooled for the three longer-term studies. 
These results favored GLA over placebo (MD −55.07, 
CI −76.87 to −33.27, p < 0.01) and provided high-quality 
evidence that six months of treatment with oils contain-
ing at least 1400 mg GLA improve self-reported 
duration of MS in RA patients. Given the previously 
mentioned caveats regarding the three-month study 
(Jäntti et al., 1989a), there is bronze level evidence that 
a shorter duration of treatment does not produce sig-
nifi cant improvement of MS.
Tender joint count out of 68, adjusted as a percentage 
change from baseline scores, reduced in favor of GLA 
in each of the three longer-term studies. Pooled results, 
using a random effects model, returned a MD of −53.80 
(CI −95.61 to −12.00, p = 0.01). These studies are sub-
stantially heterogeneous (chi-squared 6.62, I2 = 69.8%, 
p = 0.04), but in none of the studies the 95% confi dence 
intervals extended to favor placebo, indicating that 
the fi ndings are consistent but the overall effect 
(Z = 4.01) may be considered an estimate within a 
range. Likewise, pooling the data of joint tenderness 
assessed on a categorical scale (0–3, none to severe) 
and presented as percentage change from baseline 
showed improvement in the three longer-term 
studies: MD −56.64 (CI −98.10 to −15.17, p < 0.01). 
Consistent with the 68 tender joint count scores, 
these studies display substantial heterogeneity (chi-
square 5.69, I2 = 64.9%, p = 0.06) albeit within 
acceptable threshold for data pooling. The overall 
effect (Z = 4.06) should be viewed as a broad estimate 
of effect size. There is, thus, high-quality evidence 
that six months of treatment with at least 1400 mg 
GLA improves joint tenderness measured either as 
68 tender joint count or self-reported categorical 
grading of tenderness.
Swollen joint count (out of 66), adjusted as a percent-
age change from baseline scores, reduced in favor of 
GLA in two of the threee studies of approximately 
six months’ duration (Leventhal et al., 1993; Zurier 
et al., 1996). In the third study (Leventhal et al., 
scores assessed on a visual analogue scale (VAS) were 
identifi ed in any of these studies. Morning stiffness 
measured in minutes was signifi cantly reduced in two 
studies (Brzeski et al., 1991; Watson et al., 1993). Non-
signifi cant trends to improvement in the Ritchie index 
were reported in two studies (Brzeski et al., 1991; 
Watson et al., 1993). Trends to reduced pain, improved 
grip strength and patient global assessment were also 
reported in one study (Watson et al., 1993). Participants’ 
self-assessments generally favored oils containing GLA 
over placebo oils. An improvement in well-being was 
reported by almost all patients receiving blackcurrant 
seed oil (placebo group: 20%; Watson, 1993). In another 
study, 94% of patients receiving EPO reported subjec-
tive improvement (placebo group: a little over 40%); 
after a three-month placebo phase, 80% of patients 
taking EPO relapsed at least to their baseline parame-
ters (placebo group 14%; Belch et al., 1988).
In two of these studies, patients reported whether 
they reduced their NSAID consumption during the 
intervention period which lasted 6 months (Brzeski 
et al., 1991) or 12 months (Belch et al., 1988). These data 
were reported as a dichotomous variable so that the 
actual amount of dose reduction is unknown in most 
cases. In one study 11 (15) patients receiving GLA 
reported reduced or ceased NSAID intake compared 
with 5 (15) patients receiving placebo (Belch et al., 
1988). In the other study, three patients in each group 
reported reduced NSAID intake by 400 mg ibuprofen 
daily; no patient ceased NSAID use (Brzeski et al., 
1991). In this study, one patient in each of the GLA and 
placebo groups reported increased NSAID intake 
(Brzeski et al., 1991). When these data are pooled, the 
relative risk of reducing NSAIDs is higher among 
patients using GLA oils than among those using placebo 
oils (RR 1.89, CI 0.96 to 3.76). However, this risk esti-
mate is drawn from studies of small sample size with 
incomplete data reporting, and is considered less than 
bronze level evidence.
Only one study included dichotomous data for 
patients who reported AEs: 2 (16) patients in the GLA 
and 0 (18) patients in the placebo group (Belch et al., 
1988). The relative risk of AEs was higher in the GLA 
compared to the placebo group (RR 5.59, CI 0.29 to 
108.38). The same study reported the number of patients 
who withdrew from the study due to worsening disease: 
GLA group 1 (16), placebo group 10 (18), relative risk 
of worsening disease in favor of the placebo group over 
the GLA group (RR 0.11, CI 0.02 to 0.78).
Large daily dose GLA
Four studies investigated daily GLA doses between 
1400 mg and 2800 mg, and were adequately reported to 
allow data extraction and some data pooling.
In the three studies, pain was assessed on a 100 mm 
VAS and reported as percentage change from baseline. 
Using a random effects model, pooled results showed 
signifi cant improvement among patients using GLA 
oils compared with those using placebo oils (mean dif-
ference (MD) −32.83, CI −56.25 to −9.42, p = 0.006). 
Although these studies applied slightly different lengths 
of intervention (24 weeks: Leventhal et al., 1993; 1994; 
6 months: Zurier et al., 1996), results displayed little 
heterogeneity (chi-square 1.25, I2 = 0%, p = 0.54) and 
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1994) results slightly, non-signifi cantly, favored 
placebo (MD 8.00, p = 0.62), but this study was ham-
pered by small sample size (n = 14) and large 
variance in swollen joint count scores (CI −124.61 
to 140.61). When these data were pooled, this small 
sample study had some infl uence: MD was −14.43 
and the overall effect (Z = 1.66) was not statistically 
signifi cant (CI −31.43 to 2.56, p = 0.10). In all longer-
term studies, joint swelling was also scored on a scale of 
0–3 (none to severe) and converted to a percentage 
change from baseline measures. Consistent with the 66 
swollen joint count scores, results in one of the studies 
(Leventhal et al., 1994) slightly favored placebo over 
GLA, and shifted the weighted mean to midline 
when data were pooled. Applying a random effects 
model returned a MD of −24.02 (CI −70.80 to 22.76) 
and a small, non-signifi cant estimate of overall effect 
(Z = 1.01, p < 0.31).
Six out of the seven GLA studies evaluated global 
impression of the intervention. All but one of these 
(Brzeski et al., 1991) reported that patients found 
the GLA oil to be superior to the placebo oil. Due 
to differences in scales and data reporting, only data 
of three studies were available for extraction and 
pooling (Leventhal 1993; 1994; Zurier et al., 1996). 
Global evaluations of disease activity by physician 
and patient were measured using a 0–4 (none to very 
severe) scale and converted to percentage change 
from baseline scores. The MD for patient global 
evaluation was −20.87 (CI −39.43 to −2.31, p = 
0.03), thus, providing high-quality evidence that six 
months of treatment with at least 1400 mg GLA 
improves self-reported evaluation of disease severity 
over placebo among patients suffering from RA. 
Pooled data for physician global evaluation returned 
a non-signifi cant MD of −21.28 (CI −70.52 to 27.95, 
p = 0.40). Global evaluation by physician showed 
substantial and unacceptable heterogeneity between 
the studies (chi-square 11.20, I2 = 82.1%, p < 0.01). 
In only one of these three studies was the procedure 
for physician fully described, making it clear that all 
assessments of disease activity in any individual were 
undertaken by the same physician throughout the trial 
(Zurier et al., 1996). The other two studies may have 
been compromised by inter-rater variability (Leventhal 
et al., 1993; 1994).
Only one large dose study included dichotomous data 
for participants who reported AEs: 4 (14) participants 
in the GLA and 1 (13) patients in the placebo group 
(Leventhal et al., 1993). The relative risk of AEs was 
higher among patients using the GLA oil than among 
patients using the placebo oil (RR 3.71, CI 0.47 to 
29.06).
Tripterygium wilfordii Hook F extract – Oral
Although undertaken by the same research team, 
data from two studies of orally administered Tripter-
ygium wilfordii Hook F extract (TWHF) could not be 
pooled because the extracts, interventions and mea-
sures differed between the two trials (Tao et al., 1989; 
2002).
In the earlier study, a 60 mg daily extract dose of 
TWHF (solvent chloroform/methanol) was compared 
with placebo in a crossover trial, the fi rst arm of 
which lasted for 12 weeks. Clinical outcome measures 
included joint tenderness (0–3; none to severe), 
joint swelling of 60 joints only, morning stiffness in 
hours, grip strength (mmHg), and 15-meter walking 
time in seconds. Improvements were reported in 
favor of the extract with statistically signifi cant decreases 
in joint tenderness (MD −14.00, CI −19.02 to −8.98, 
p < 0.01) and swollen joint count (MD −3.10, CI −5.53 
to −0.67, p = 0.01). Non-signifi cant decreases were 
reported in morning stiffness (MD −1.40, CI −4.18 
to 1.38, p = 0.32) and walking time (MD −10.40, 
CI −22.07 to 1.27, p = 0.08). An increase in grip 
strength was also demonstrated (MD 3.20, CI −20.01 
to 26.41), although this was not statistically signifi cant 
(Z = 0.27, p = 0.79).
In the later study, larger extract doses of TWHF 
(solvent ethanol/ethyl/acetate) were used, 180 mg 
(n = 10) and 360 mg (n = 10) per day. Clinical outcomes 
were assessed using the ACR core set of measures at 
the 20%, 50% and 70% improvement levels (Tao 2002). 
Eight high-dose and four low-dose patients satisfi ed 
the ACR20 improvement criteria at the end of the 
intervention period compared to none of the patients in 
the placebo group. These dichotomous data convert to 
an odds ratio of 17.31 (CI 0.80 to 373.45) and 85.00 (CI 
3.61 to 2001.33) of satisfying ACR20 improvement cri-
teria when patients consume the extract in a dose of 
180 mg or 360 mg TWHF, respectively, compared with 
placebo.
Graphic presentation of between group comparisons 
of each of the disease activity component measures 
(tender joint count, swollen joint count, pain, physical 
function, patient global, physician global, erythrocyte 
sedimentation rate, C-reactive protein) indicated that 
all outcomes were improved in the high-dose group 
over both the low-dose and placebo groups, and that 
improvements were observed on all measures in the 
low-dose group over the placebo group. These data 
were not reported in a form that allowed extraction for 
re-analysis.
In both studies, more AEs were seen among patients 
receiving TWHF than patients receiving placebo. In 
the earlier study, AEs resulted in four withdrawals, 
and a severe reaction (fever and aplastic anaemia) 
occurred in one patient following an overdose of TWHF. 
One death occurred also, although not thought to be 
related to the intervention. In the later study, four 
patients in the placebo group reported AEs, as did six 
patients in the high-dose and fi ve patients in the 
low-dose group. In this study, none of the AEs 
was reported as severe (not require hospitalization). 
Commonly reported AEs included diarrhoea, head-
ache, and hair loss.
Phytodolor NR
Two studies compared a daily dose of 30 drops of the 
herbal mixture Phytodolor NR to placebo, one over two 
weeks (Meier, 1987) and the other over 12 months 
(Eberl et al., 1988). Both studies are unpublished ran-
domized controlled clinical trials conducted by the 
manufacturer (Steigerwald Pharmaceuticals) as part of 
product development and testing.
Because length of intervention and some of the mea-
sures differed between the trials, data could not be 
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pooled for meta-analyses. Available mean data are 
reported for descriptive comparison. For one study, 
mean changes from baseline were calculated from fre-
quency tables (Eberl et al., 1988). Standard deviations 
could not be calculated from the data provided.
Both studies reported cumulative use of NSAIDs 
(diclofenac) over the course of the trials and reported 
greater total NSAID use in the Phytodolor NR than 
in the placebo groups. In the longer-term trial, there 
was evidence that NSAID use in the Phytodolor 
NR group fell below that of the placebo group from 
months 2 to 11, but reasons for the lower NSAID 
consumption are not well explained in the study (Eberl 
et al., 1988).
For several herbal medicines, only one study was 
available.
SKI306X
In a single, well-designed, multicentre trial, the Korean 
herbal mixture SKI 306X was tested against celecoxib 
in a six-week head-to-head comparison (Song et al., 
2007). Pain, measured using a 100 mm VAS, decreased 
signifi cantly in both groups over time (p < 0.01), but was 
not signifi cantly different between groups. These results 
provide moderate quality evidence that SKI306X is 
comparable to celecoxib for pain reduction in patients 
with RA.
After three weeks of intervention, 16 patients receiv-
ing SKI306X and 24 patients receiving celecoxib 
satisfi ed the ARC20 improvement criteria, whereas 
another three weeks later equal patient numbers in both 
groups (n = 29) satisfi ed these criteria. Considering each 
of these criteria individually (28 tender and swollen 
joint counts; patients’ global assessment; investigators’ 
global assessment; HAQ-DI score; Westergren ESR, 
CRP), there were no signifi cant differences between the 
two groups at baseline, week 3 or week 6, on any mea-
sures except erythrocyte sedimentation rate. Mean ESR 
was slightly, but not signifi cantly, higher in the SKI306X 
group at baseline, and dropped to signifi cantly less than 
the mean ESR in the celecoxib group at both, week 3 
(p < 0.04) and week 6 (p = 0.01). These results offer 
moderate quality evidence that SKI306X and celecoxib 
have comparable effects on reducing disease activity in 
patients with RA.
AEs did not differ signifi cantly between the two 
groups. Gastrointestinal complaints (epigastric pain, 
abdominal discomfort, nausea, anorexia, dyspepsia) 
were most common. In the SKI306X group, two patients 
discontinued the study medication because of depres-
sion (serious drug-related event) and because of epigas-
tric pain. The reasons for the three withdrawals in the 
celecoxib group were pruritus, abdominal discomfort, 
and skin rash.
Willow bark extract
A proprietary extract of willow bark (Salix daphnoides) 
with 240 mg salicin in the daily dosage was compared 
with placebo in a small sample (n = 26) of patients with 
RA (Biegert et al., 2004). After six weeks of treatment, 
the extract was not signifi cantly more effective than 
placebo in producing change from baseline in any clini-
cal outcome (pain VAS 0-100; 28 tender and swollen 
joint counts; patient and physician assessments of 
effi cacy; HAQ-DI score; SF-36 physical and mental 
component summary scores). This lack of statistical 
signifi cance may be a Type II error in a small sample, 
underpowered study.
Three patients (willow bark n = 2, group placebo n = 
1) satisfi ed ACR20 response criteria after six weeks of 
intervention. Similar numbers (n = 7) and severity of 
AEs were reported for both groups, although it is 
unclear how many patients these reported.
Uncaria tomentosa extract
A proprietary extract of Uncaria tomentosa (cat’s 
claw) was compared with placebo in a double-blind 
randomized controlled trial (Mur et al., 2002). Signifi -
cant improvements were reported in 68 tender joint 
count both within and between groups after 24 weeks 
of treatment (p = 0.044). Also, signifi cant within group 
improvements were found in the group consuming 
cats claw on measures of 66 tender joint count (p = 
0.001), Ritchie index (p = 0.002) and duration of morning 
stiffness (p = 0.002). No improvements either bet-
ween or within groups, were reported for any other 
clinical or laboratory variables. Twelve patients in 
each group reported AEs, and one patient from 
each group withdrew from the study because of 
the AE.
Powdered Tanacetum parthenium
Daily use of dried, powdered feverfew (Tanacetum 
parthenium) was compared with placebo (cabbage) 
in 41 patients with RA (Patrick et al., 1989). Of the 
clinical outcomes measured in this study (duration of 
morning and inactivity stiffness, pain (10 cm VAS), grip 
strength, Rtichie index). Grip strength was reported 
to be signifi cantly improved in the feverfew group 
over time (p = 0.03) and in comparison to the placebo 
group after six weeks of intervention (p = 0.047). But 
recalculation of the between group comparison for this 
review returned a non-signifi cant p value of 0.19. No 
signifi cant differences were reported either between or 
within groups on any other clinical measures. One 
patient in each group reported mild AEs; the patient in 
the placebo group withdrew from the study because 
of this.
RA-1
An Ayurvedic herbal mixture, RA-1, was compared 
with placebo in patients with RA (Chopra et al., 2000). 
Data from 182 patients were included in an intention-
to-treat analysis although only 165 participants com-
pleted the full 16-week trial (per protocol). Change 
scores on all clinical variables were greater in the RA-1 
group than in the placebo group after 16 weeks of inter-
vention, but not statistically signifi cant.
In the per protocol sample, clinical outcomes were 
further assessed using the ACR core set of measures at 
the 20% and 50% improvement levels (Chopra et al., 
2000). Thirty-nine (group RA-1 n = 80) and 30 (group 
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placebo n = 85) patients satisfi ed the ACR20 improve-
ment criteria at the end of the intervention period. 
These dichotomous data convert to an odds ratio of 1.74 
(CI 0.93 to 3.26, p = 0.08) of patients in the RA-1 group 
satisfying ACR20 improvement criteria. A signifi cant 
difference was also noted between the groups for the 
number of ACR50 responders: 15 (group RA-1) and 5 
(group placebo) corresponding to an odds ratio of 3.69 
(CI 1.27 to 10.70, p = 0.02). These results may be con-
sidered to represent silver level evidence that 16 weeks 
of daily use of RA-1 is superior to placebo for reducing 
disease activity in RA measured as ACR50 response 
criteria.
Boswellia serrata extract
A proprietary gum resin extract of Boswellia serrata 
(H15) was tested in 78 patients with active RA in two 
randomized controlled trials in four centres. Results 
from 37 patients in one centre (Ratingen) were re- 
analyzed, and demonstrated no signifi cant effectiveness 
over placebo in either clinical or laboratory outcomes 
(Sander et al., 1998). Data were not normal distributed, 
and consequently reported as median and range. Data 
in this form could not be extracted for analysis in this 
review. Median subjective pain assessments (VAS 0–10) 
worsened from 4.6 to 4.7 in the Boswellia group and 
improved from 3.9 to 3.8 in the placebo group; however, 
these small changes in pain may be unimportant in light 
of the baseline differences between groups on this 
measure. Median subjective global assessment improved 
in both groups, from 5.0 to 4.9 in the Boswellia group 
and from 4.7 to 4.2 in the placebo group.
CAPSAICIN – TOPICAL
Topical capsaicin for control of RA hand pain was com-
pared to placebo in two studies. In both studies, the 
placebos were vehicle creams prepared and packaged 
to appear indistinguishable from the active agent, but 
blinding and placebo validity may have been compro-
mised by a local burning sensation that may occur as an 
AE with topical capsaicin application. In one study, 
burning at the site of application was noted by 44% of 
patients treated with capsaicin and by one treated with 
placebo (Deal et al., 1991).
In the larger of the two trials (n = 31; Deal et al., 
1991), four-times-daily topical use of 0.025% wv capsa-
icin cream demonstrated a trend to improve pain. Per-
centage changes showed a MD of −25.00 (CI −51.76 to 
1.76, p = 0.07) for pain assessed on a 100 mm VAS and 
a MD of −0.47 (CI −1.08 to 0.14, p = 0.13) for pain 
assessed on a categorical pain scale. Small sample size 
means that this study was probably underpowered, 
increasing the likelihood of Type II error. Change from 
baseline of the physician’s global evaluation (−1 to 3, 
higher score indicating greater improvement) also 
favored the treatment group, and the difference between 
groups in this measure was statistically signifi cant after 
four weeks of intervention (MD = 1.36, CI 0.52 to 2.20, 
p = 0.001). Burning at the site of application of the 
cream was the only AE reaction reported in this 
study.
A further study compared a higher dose (0.075% wv) 
capsaicin cream to placebo (McCarthy and McCarthy, 
1992). The sample size was very small; of the seven 
patients, fi ve completed the four-week trial. Although 
improvements in pain were measured on a 100 mm 
VAS, data from this study were not adequately reported 
to allow extraction for pooled analysis with the larger 
study.
Tripterygium wilfordii – Topical
Sixty-one patients with RA participated in a six-week, 
randomized, double-blind, placebo-controlled trial of a 
topically applied tincture of Tripterygium wilfordii 
(Cibere et al., 2003). The placebo tincture was prepared 
and packaged to be indistinguishable from the interven-
tion. The tincture was applied up to six times per day 
to the swollen or tender joints, and results were reported 
using the core set of ACR response criteria, aggregated 
into a slightly modifi ed form of the 20% improvement 
level. At the end of the intervention period, statistically 
signifi cant differences were identifi ed between the two 
groups on most clinical outcomes: 42 tender joint count 
(MD 1.50, CI 0.58 to 2.42, p = 0.001), 40 swollen joint 
count (MD 4.40, CI 2.76 to 6.04, p < 0.001), grip strength 
in kiloPascals (MD 39, CI 25.70 to 52.30, p < 0.001), and 
duration of morning stiffness in hours (MD 0.80, CI 0.54 
to 1.06, p < 0.001). A signifi cant difference was noted 
between the groups for the number of ACR20 respond-
ers; 18 of 31 patients in the Tripterygium group and 6 
of 30 patients in the placebo group. These data repre-
sent an odds ratio of 5.54 (CI 1.76 to 17.39, p = 0.003) 
for the Tripterygium group in satisfying ACR20 
improvement criteria. These results may be considered 
as silver level evidence that six weeks of daily topical 
Tripterygium application is superior to placebo for 
reducing RA disease activity.
Summary tables and details of the calculations are 
presented on the webpage www.uniklinik-freiburg.
de/rechtsmedizin/live/forschung/phytomedicine/
originalartikel.html. No serious AEs were reported with 
any herbal intervention except with oral Tripterygium 
wilfordii extract.
DISCUSSION
Several of the studies included in this review were 
poorly described, and incomplete reporting may have 
led to those studies being undervalued. In particular, we 
made strict judgements of methodological quality on 
the basis of reporting (Higgins and Green, 2008), but 
not all reviewers agreed that this approach was the most 
suitable. In 1990, the International Conference on 
Harmonisation (ICH) of Technical Requirements for 
Registration of Pharmaceuticals for Human Use was 
established to bring together regulatory authorities in 
Europe, Japan and the United States and experts from 
the pharmaceutical industry to determine scientifi c and 
technical aspects of product registration. In these coun-
tries, ICH guidelines are implemented in the law, and 
Human Research Ethics Committees would not approve 
a clinical trial protocol discordant with the ICH good 
clinical practice consolidated guidelines (ICH, 2004). 
One reviewer argued that for studies conducted in the 
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European Union, Japan, Canada, or the USA after 
1990, we could assume that randomization, blinding, 
masking of outcome assessment, and allocation con-
cealment were adequately conducted even if it the study 
was simply reported as ‘randomized and double-blind’. 
In order to be consistent in our treatment of all studies 
included in this review, we based our judgements 
on information reported in the manuscripts, but we 
acknowledge that systemic regulation of clinical trials is 
likely to improve the quality of study design. For 
example, we recognize that properly constituted Human 
Research Ethics Committees would only approve study 
protocols with adequate explanation of inclusion and 
exclusion criteria, reliable and valid outcome measures, 
and appropriate planned statistical analyses. The 
increasingly common requirements to register clinical 
trial protocols and provide evidence of ethics commit-
tee approval prior to publishing study reports in repu-
table medical journals is also helping to increase 
transparency. To allow full and accurate assessment of 
future studies, we recommend that authors conform 
to the Consolidated Standards of Reporting Trials 
(CONSORT; Begg et al., 1996; Moher, 2001).
Three studies in this review were of confi rmatory 
design, meaning that they were fully powered studies 
planned to further investigate trends to effectiveness 
demonstrated in earlier studies (Biegert et al., 2004; 
Cibere et al., 2003; Song et al., 2007). Several studies, 
although well designed, were probably underpowered 
due to small sample size and diffi culties with recruit-
ment and lack of evidence of effect may be due to Type 
II error. Trends to effectiveness may be suggested from 
underpowered studies if improvements can be calcu-
lated and reported as effect sizes (Andersen and Stoové, 
1998; Stoové and Andersen, 2003). Even small effect 
sizes may represent clinically meaningful improve-
ments, particularly if these small effects represent 
improvements in a condition with a substantial burden 
of disease (e.g., RA).
The review demonstrates that there is sparse evidence 
supporting the use of herbal medicines in the treatment 
of RA. For only fi ve of the HMPs studied, was more than 
one study available. Due to the heterogenity of the 
studies, different doses and differences in the active 
principle of the HMPs which is related to the individual 
solvent and drug-extract ratio, further clinical trials are 
needed for a convincing evidence of effectiveness. For 
all herbal medicines, the optimum dose and duration of 
treatment needs to be defi ned. Several studies were of 
poor quality and were inconsistent with current clinical 
trial standards in rheumatology. Only fi ve studies used 
the set of outcome measure recommended by the Amer-
ican College of Rheumatology (ACR) since 1995 
(Chopra et al., 2000; Tao et al., 2002; Cibere et al., 2003; 
Biegert et al., 2004; Song et al., 2007): 20% improvement 
in tender and swollen joint counts and 20% improve-
ment in three of fi ve ACR core set measures including 
patient and physician global assessments, pain and dis-
ability measures, and laboratory evaluation of an acute 
phase reactant (ESR, CRP: Felson et al., 1993; 1995). In 
two of these studies, the ACR20 included the HAQ-DI 
as a measure of disability (Cibere et al., 2003; Song et al., 
2007). For future studies, we recommend that research-
ers use ACR outcome measures to allow comparison of 
effect sizes between different herbal medicines, and to 
provide estimates of clinical relevance.
Concerns have been raised about the costs and associ-
ated adverse reactions to herbal medicines (Atherton, 
1994; Ernst, 1995; 1996; 1998). In general, people with 
RA have three times the direct medical costs, twice the 
hospitalization rate and ten times the work disability 
rates compared to the age- and sex-matched population 
(Feltsand Yelin, 1989). Although the use of plants as 
medicines is fundamental to traditional healthcare 
systems throughout the world, the costs of herbal inter-
ventions are rarely covered by modern public health 
systems. We recommend that future trials of herbal 
therapies for RA include measures of the costs of care 
so that the direct costs of these interventions might be 
compared with the already high costs of other RA 
treatments.
All RA medicines are associated with AEs and 
routine prevention measures such as screening for 
hypertension, osteoporosis, renal insuffi ciency or cancer 
should be included in the reassessments (Tugwell, 
2004). Although some of the trials include AE data, 
adequate evidence on safety is not available for any of 
the herbal medicinal products considered in this review. 
According to international guidelines (ICH, 2004), 
results from genotoxicity studies, toxicokinetic, and 
mechanistic studies are essential for preclinical safety 
assessment. Carcinogenicity studies are only required 
when human exposure warrants the need for informa-
tion from lifetime studies in animals in order to assess 
the carcinogenic potential. Also recommended are 
pharmacological trials of six and nine months for chronic 
toxicity assessment in rodents and non-rodents respec-
tively. None of the herbal medicinal products consid-
ered in this review have been subject to this rigorous 
non-clinical testing, and therefore, cannot be recom-
mended during pregnancy or lactation.
Herbal preparations may also be contaminated with 
other herbs, pesticides, herbicides, heavy metals, or 
drugs. Contamination is unlikely if the holder of manu-
facturing authorization complies with the principles and 
guidelines of good manufacturing practice (GMP) for 
medicinal products, and uses starting materials which 
have been manufactured in accordance with the GMP 
guidelines (EFPIA, 1996).
The safety profi le for preparations from Tripterygium 
wilfordii Hook F is particularly concerning. This herb is 
no longer included in the English edition of the Chinese 
Pharmacopeia, probably due to the toxicity of the co-
active triptolides. AEs include dysmenorhea, decrease 
of male fertility, renal insuffi ciency, haematotoxicity, 
embryotoxicity and immune suppression demonstrated 
by increased rate of infections (Canter et al., 2006). 
The rodent LD50 for the ethyl alcohol and chloro-
form extracts were 608–858 mg/kg and 160 mg/kg, 
respectively, depending on the source of the plant and 
the time of harvest. Subacute toxicity showed pathologi-
cal changes mainly in the lymphatic and reproductive 
systems. The risk-benefi t trade-off of Tripterygium 
wilfordii Hook F may be judged as unfavorable (Canter 
et al., 2006).
The US National Library of Medicine and the 
National Institutes of Health summarized safety data 
for EPO (www.nlm.nih.gov/medlineplus/druginfo/
natural/patient-primrose.html). Allergy or hypersensi-
tivity seems to be rare, but contact dermatitis (skin rash) 
is possible. Several reports described seizures in indi-
viduals taking EPO, particularly in people with a history 
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of seizure disorders, and among individuals taking EPO 
in combination with anaesthetics or other centrally 
acting drugs such as chlorpromazine, thioridazine, 
trifl uoperazine, or fl uphenazine. Doses of antiseizure 
medications may require an increase of the dosage. 
People who plan to undergo surgery requiring general 
anaesthesia are advised to stop taking EPO two weeks 
prior. Other adverse events include occasional head-
ache, abdominal pain, nausea, and loose stools. In 
animal studies, GLA decreased blood pressure. Early 
results in human studies do not show consistent changes 
in blood pressure but people on blood pressure medica-
tions should closely monitor their blood pressure. Since 
borage and blackcurrant seed oils also contain GLA, 
the adverse event profi les may be similar.
Optimum duration of treatment with GLA is uncer-
tain. Benefi ts appeared to be increased if dosages were 
in excess of 1.4 g daily and were administered for at 
least six months’ duration although it seems that 
maximum benefi t may not be achieved within this time 
period. One problem seen in studies where larger doses 
of GLA were given was related to the large quantity, 
and large size, of capsules required to achieve higher 
dosages. Future studies might address this problem by 
evaluating the effects of lower dosages over a longer 
period of time.
Feverfew is a traditional medicine for the prevention 
of migraine, although its effectiveness has not yet been 
proven beyond any doubt (Pittler and Ernst, 2004). Pre-
clinical safety data are not available (ESCOP, 2003). 
Rare cases of allergy, diarrhoea, fl atulence, nausea or 
vomiting have been noted. Cases of abdominal pain and 
indigestion in patients who have taken feverfew for long 
periods have been reported (ESCOP, 2003). From time 
to time a pause in treatment is advisable with gradual 
reduction of dosage during the preceding month. It 
remains to be established if feverfew is an alternative 
treatment option for RA.
Willow bark extract contains a gastroprotective prin-
ciple (Glinko, 1998; Gürbüz et al., 2003) which may be 
of advantage in light of the gastrointestinal adverse 
events possible among people concomitantly using 
NSAIDs (Ofman et al., 2002). According to the ESCOP 
monograph, treatment with willow bark extract is not 
restricted (ESCOP, 2003). Severe specifi c effects have 
not yet been observed in the doses employed except in 
rare cases allergic skin reactions. In people with known 
sensitivity to salicylates, the use of willow bark prepara-
tions should be avoided. Although willow bark has only 
little impact on blood clotting (Krivoy et al., 2001), 
interaction studies investigating doses systematically 
are needed to rule out any skepticism. Dental extrac-
tions or operations do not appear to be contraindicated, 
but robust preclinical safety data are needed.
The adverse effect profi le for Phytodolor NR appears 
to be better than for NSAIDs. Gastrointestinal com-
plaints were most frequently reported (2.6%), and occa-
sionally, allergic skin reactions have occurred. Some 
adverse effects are partly due to the alcohol content of 
Phytodolor NR (45.6% vol, 0.7 g per 40 drops) which 
may pose a health risk to children, and to adults with 
liver disease, alcoholism, epilepsy, or brain-damage. 
Caution is advised during pregnancy or lactation and 
for drivers and individuals who operate machines, even 
though no impairment of consciousness or reactivity is 
expected to occur with 0.7 g of alcohol per dose. Studies 
on mutagenicity, teratogenicity and toxicity in the 
parent animals and their progeny gave no evidence 
for any toxic effects arising from the intake of the 
combination during pregnancy and the lactation period 
(Gundermann, 2001).
Although SKI306X appeared not to be associated 
with a higher incidence of adverse events than cele-
coxib, neither preclinical safety data are available nor 
interaction studies or long-term studies that prove the 
safety this HMP. This is a major concern and needs to 
be ruled out before herbal mixtures such as SKI306X 
are applied to humans. The active principle of every 
HMP corresponds to the sum of effects of compounds 
that may synergistically or antagonistically interact. If 
three herbal extracts are combined, the superiority of 
the combination over the individual herbal extracts has 
to be proven: in vitro, in animal experiments and in 
human pharmacological studies.
Cat’s claw preparations inhibit cytochrome P450 3A4 
activities (Budzinski et al., 2000). Such activities are 
important for drug metabolism by the liver and can 
prolong the biological activity of drugs. No unwanted 
physiological changes, organ changes, or toxic effects 
have been observed when using an aqueous extract in 
rats (Sheng et al., 2000): the LD50 was reported to be 
greater than 8 g/kg. An increase of white blood cells, 
however, was seen in humans and considered clinically 
signifi cant because data suggest that cat’s claw can stim-
ulate the immune system (Lemaire et al., 1999). Other 
in vitro experiments using Chinese hamster ovary cells 
and bacteria failed to demonstrate any toxicity (Rizzi 
et al., 1993; Santa Maria et al., 1997). The available 
animal toxicological studies do not indicate severe 
toxicity from oral intake of cat’s claw preparations 
but suggest a low potential for acute and subacute oral 
toxicity. This evidence does not suggest genotoxic 
potential or mutagenic activity.
No data on safety are available for Ayurvedic medi-
cines. The RA-1 product was not standardized (Chopra 
et al., 2000); therefore, the study cannot be accurately 
replicated to confi rm results because co-active ingredi-
ents may differ between product batches. Also, there is 
no way to determine whether the product has been 
contaminated with pesticides, herbicides or heavy 
metals. Contamination is not an issue if manufacturers 
comply with the principles and guidelines of good man-
ufacturing practice (EFPIA, 1996); a requirement in 
almost all industrialized countries, but not in India 
where the study was undertaken.
Capsaicin may cause skin irritation. It may be 
absorbed through skin (particularly abraded skin) 
and activate dermal pain fi bers and cause a burning 
sensation. There is some concern that capsaicin may be 
potentially neurotoxic, although clinical studies with 
topical capsaicin have not shown this to occur. It is 
thought to be capable of elevating the heat-pain thresh-
old in treated skin areas. Capsaicin may cause irritation 
of the eyes with redness, pain, lacrimation, tearing, and 
blepharospasm. After inhalation it may cause respira-
tory tract and mucous membrane irritation with cough-
ing, wheezing, burning sensation in nose and throat, and 
laryngitis (ESCOP, 2003). Capsaicin given to newborn 
rats results in an irreversible loss of specifi c sensory 
functions by selective degeneration of approximately 
50% of sensory ganglion cells (Lawson and Nickels, 
1980; Fitzgerald, 1983). The administration of capsaicin 
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in adult rats induces progressive rapid deterioration of 
structural integrity of some B-type primary sensory 
neurons, leading to the degeneration of these cells 
(Jansco and Kiraly, 1981). Long-term studies on neuro-
toxicity are required to rule out any possible harm in 
humans.
The current available evidence for herbal treatment of 
RA is generally sparse and reliant on small sample sizes 
and is therefore insuffi cient for reliable assessment of 
effi cacy to be made. The studies of GLA are of suffi cient 
interest to warrant further investigation. Variability 
between studies indicates a need to establish effi cacy, 
optimum dosage and duration of treatment. The single 
studies are inconclusive. Good tolerance of most of the 
herbal remedies was demonstrated although caution is 
warranted in interpreting safety due to small sample size 
in some of the studies. The trend for self-medication with 
over-the-counter herbal remedies, especially in the treat-
ment of chronic disease, makes further research in the 
fi eld desirable. Non-clinical studies are required to deter-
mine the toxicity profi les of almost all herbal medicines 
in common use for the treatment of RA.
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